Dallas, Texas: StockGuru announces The StockGuru Spotlight for Tuesday September 4, 2012: Pristine Solutions (OTCBB: PRTN).
Eaton Scientific Systems, Ltd. (“Eaton Scientific” or the “Company”), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to provide this update detailing recent comments made by Dr. Hootan Melamed, whose family’s Beverly Hills, CA based Rox San Pharmacy is the original compounding Pharmacy for Tropine 3, a Novel indication of Homatropine in oral suspension. Dr. Melamed filed the Patent for the drug’s new indication for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
“Over the last six years, the Rox San Pharmacy team has been compounding Tropine 3 for southern California doctors that prescribe the drug to their patients for the treatment of hot flashes. Based on our interactions with the doctors and patients, it is our belief that Tropine 3 users have had a generally very positive response to the drug with no pronounced negative side-effects,” stated Dr. Hootan Melamed. “It is obvious that women across America and around the world could benefit from open access to this new drug, so we are very excited to see Eaton Scientific making progress in executing its plan to seek FDA Approval and fully commercialize Tropine 3. We would like to see our experience with the positive effects of the oral suspension version of Homatropine that Eaton has named Tropine 3 in a FDA Clinical Trial and move towards having Tropine 3 available for all women suffering from the effects of hot flashes.”
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
For more information on PRTN, please visit: http://stockguru.com//tag/prtn/
What is The StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worthy of our readers attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated StockGuru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. The companies that are discussed in this opinion have not approved the statements made in this release or blog post. This release or blog post contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.